Free Trial
NASDAQ:INVA

Innoviva (INVA) Stock Price, News & Analysis

Innoviva logo
$20.43 +0.40 (+2.00%)
Closing price 04:00 PM Eastern
Extended Trading
$20.42 0.00 (-0.02%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Innoviva Stock (NASDAQ:INVA)

Key Stats

Today's Range
$19.87
$20.48
50-Day Range
$18.17
$20.92
52-Week Range
$16.67
$22.00
Volume
650,802 shs
Average Volume
816,083 shs
Market Capitalization
$1.29 billion
P/E Ratio
65.91
Dividend Yield
N/A
Price Target
$42.75
Consensus Rating
Buy

Company Overview

Innoviva Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
95th Percentile Overall Score

INVA MarketRank™: 

Innoviva scored higher than 95% of companies evaluated by MarketBeat, and ranked 120th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Innoviva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Innoviva has only been the subject of 3 research reports in the past 90 days.

  • Read more about Innoviva's stock forecast and price target.
  • Earnings Growth

    Earnings for Innoviva are expected to grow by 369.70% in the coming year, from $0.33 to $1.55 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Innoviva is 65.91, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.48.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Innoviva is 65.91, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 79.66.

  • Price to Book Value per Share Ratio

    Innoviva has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Innoviva's valuation and earnings.
  • Percentage of Shares Shorted

    15.56% of the float of Innoviva has been sold short.
  • Short Interest Ratio / Days to Cover

    Innoviva has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Innoviva has recently decreased by 2.42%, indicating that investor sentiment is improving.
  • Dividend Yield

    Innoviva does not currently pay a dividend.

  • Dividend Growth

    Innoviva does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.56% of the float of Innoviva has been sold short.
  • Short Interest Ratio / Days to Cover

    Innoviva has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Innoviva has recently decreased by 2.42%, indicating that investor sentiment is improving.
  • News Sentiment

    Innoviva has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.04 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Innoviva this week, compared to 4 articles on an average week.
  • Search Interest

    7 people have searched for INVA on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Innoviva to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Innoviva insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.25% of the stock of Innoviva is held by insiders.

  • Percentage Held by Institutions

    99.12% of the stock of Innoviva is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Innoviva's insider trading history.
Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INVA Stock News Headlines

Innoviva to Participate in Upcoming Investor Conferences
BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist Ben Stein—drawing on insights from his own experience and his father’s time advising two U.S. presidents—just released a new report on how to help protect your retirement from the next major crisis.tc pixel
Innoviva (NASDAQ:INVA) Lowered to Buy Rating by Wall Street Zen
See More Headlines

INVA Stock Analysis - Frequently Asked Questions

Innoviva's stock was trading at $17.35 at the beginning of the year. Since then, INVA stock has increased by 17.8% and is now trading at $20.43.

Innoviva, Inc. (NASDAQ:INVA) announced its quarterly earnings results on Wednesday, August, 6th. The biotechnology company reported $0.77 earnings per share for the quarter, topping analysts' consensus estimates of $0.57 by $0.20. The biotechnology company earned $100.28 million during the quarter, compared to the consensus estimate of $87.10 million. Innoviva had a trailing twelve-month return on equity of 18.67% and a net margin of 10.44%.

Innoviva's top institutional shareholders include Franklin Resources Inc. (4.50%), American Century Companies Inc. (3.29%), Systematic Financial Management LP (3.28%) and Arrowstreet Capital Limited Partnership (2.72%).
View institutional ownership trends
.

Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Innoviva investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Visa (V).

Company Calendar

Last Earnings
8/06/2025
Today
8/29/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Large Cap Pharma
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:INVA
Previous Symbol
NASDAQ:THRX
CIK
1080014
Employees
100
Year Founded
1996

Price Target and Rating

High Price Target
$55.00
Low Price Target
$26.00
Potential Upside/Downside
+110.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.31
Trailing P/E Ratio
65.49
Forward P/E Ratio
61.52
P/E Growth
N/A
Net Income
$23.39 million
Net Margins
10.44%
Pretax Margin
17.71%
Return on Equity
18.67%
Return on Assets
9.92%

Debt

Debt-to-Equity Ratio
0.36
Current Ratio
2.64
Quick Ratio
2.44

Sales & Book Value

Annual Sales
$370.23 million
Price / Sales
3.46
Cash Flow
$3.51 per share
Price / Cash Flow
5.79
Book Value
$11.34 per share
Price / Book
1.79

Miscellaneous

Outstanding Shares
63,021,000
Free Float
61,603,000
Market Cap
$1.28 billion
Optionable
Optionable
Beta
0.38

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:INVA) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners